Table 1.

Clinic-pathological characteristics of patients

	Nivolumab or pembrolizumab N (%)
Total	41 (100)
Median age
Range (23–85)	64
Gender
Male	26 (63.4)
Female	15 (36.6)
Disease stage
III	6 (14.6)
IV	35 (85.4)
Line of treatment
I	17 (41.5)
II	17 (41.5)
>III	7 (17)